Supplementary Material

Second Generation Analogs of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery

James M. Kraus[1], Hari Babu Tatipaka[1], Naveen Kumar Chennamaneni[1], Mandana Karimi[2], Sarah A. Mcguffin[1], , Frederick S. Buckner[2], Michael H. Gelb[1,3*]*

Table of Contents:

4-(3-Chlorophenyl)-6-((4-chlorophenyl)(hydroxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (19). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.45; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.95 (d, *J* = 1.2 Hz, 1H), 7.78 (m, 2H), 7.51 (ddd, *J* = 1.5, 1.5, 9.0 Hz, 1H), 7.47 (d, *J* = 7.2 Hz, 1H), 7.41 (m, 2H), 7.35 (dd, *J* = 1.5, 1.5 Hz, 1H), 7.26 (m, 4H), 6.85 (d, *J* = 1.5 Hz, 1H), 6.66 (s, 1H), 3.83 (s, 3H), 3.69 (s, 3H) ESI-MS m/z 490.5 $(M + H^+)^+$ MW: 490.4 g/mol. Mono-TFA salt FW: 604.40 g/mol.

4-(phenyl)-6-((4-chlorophenyl)(hydroxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one. TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.45; ^{1}H NMR (300 MHz, CD_3OD, δ): 7.76 (dd, 1H), 7.70 (d, 1H), 7.63 (s, 1H), 7.46 (m, 3H), 7.38 (d, *J* = 2.1 Hz 1H), 7.31 (m, 4H), 7.20 (m, 2H), 6.94 (d, *J* = 0.6 Hz 1H), 6.63 (s, 1H), 3.83 (s, 3H), 3.44 (s, 3H) ESI-MS m/z 457.0 $(M + H^+)^+$ MW: 455.94 g/mol.

4-(phenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (10) 6.5 mg (0.014 mmols) of the previous compound was dissolved in 10 mL of MeOH and 6.5 mg tosic acid was added. The reaction was heated to reflux for 48 hours. One spot by TLC. Solvents were removed under reduced pressure to produce a colorless, oily semi-solid. Product was purified by HPLC using a water-methanol gradient with 0.08% v/v trifluoroacetic acid. 0-5 minutes 20% MeOH, 5-25 minutes 20-65% MeOH, 25-30 minutes 65-100% MeOH. Product elutes at 27.8 minutes. 5.6 mg (0.0096 mmols) produced as a mono-TFA salt. Yield 67%. TLC (CH_2Cl_2: MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.00 (s, 1H), 7.80 (dd, 1H), 7.75 (d, 1H), 7.57 (m, 5H), 7.40 (m, 6H), 6.70 (s, 1H), 3.82 (s, 3H), 3.55 (s, 3H) 3.22 (s, 3H) ESI-MS m/z 470.4 $(M + H^+)^+$ MW: 469.96 g/mol. Mono-TFA salt FW: 583.99 g/mol.

4-(4-chlorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (11). TLC (CH_2Cl_2: MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.00 (s, 1H), 7.83 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.73 (d, *J* = 9 Hz, 1H), 7.62 (d, *J* = 1.5 Hz, 1H), 7.54 (m, 3H), 7.39 (m, 6H), 6.67 (s, 1H), 3.81 (s, 3H), 3.56 (s, 3H) 3.23 (s, 3H) ESI-MS m/z 504.6 $(M + H^+)^+$ MW: 504.41 g/mol. Mono-TFA salt FW: 618.43 g/mol.

4-(3-chlorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (3). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.01 (s, 1H), 7.85 (dd, *J* = 9.1 Hz, 2.1 Hz, 1H), 7.74 (d, *J* = 9.0 Hz, 1H), 7.62 (d, *J* = 1.5 Hz, 1H), 7.53 (m, 3H), 7.44 (m, 1H), 7.40 (s, 4H), 7.35 (m, 1H), 6.68 (s, 1H), 3.81 (s, 3H), 3.56 (s, 3H) 3.24 (s, 3H) ESI-MS m/z 504.6 $(M + H^+)^+$ MW: 504.41 g/mol. Mono-TFA salt FW: 618.43 g/mol.

4-(4-Fluorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (12). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.00 (s, 1H), 7.82 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.73 (d, *J* = 9 Hz 1H), 7.61 (d, *J* = 1.2 Hz, 1H), 7.53 (d, *J* = 2.1 Hz, 1H), 7.43 (m, 6H), 7.28 (m, 2H), 6.65 (s, 1H), 3.81 (s, 3H), 3.56 (m, 3H) 3.23 (s, 3H), ESI-MS m/z 488.5 $(M + H^+)^+$ MW: 487.95 g/mol. Mono-TFA salt FW: 601.98 g/mol.

4-(3-fluorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (6). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.96 (s, 1H), 7.79 (dd, *J* = 9.0, 2.1 Hz, 1H), 7.70 (d, *J* = 8.7 Hz 1H), 7.57 (d, *J* = 1.5 Hz 1H), 7.50 (m, 2H), 7.36 (s, 4H), 7.20 (m, 3H), 6.64 (s, 1H), 3.77 (s, 3H), 3.51 (s, 3H) 3.19 (s, 3H) ESI-MS m/z 488.5 $(M + H^+)^+$ MW: 487.95 g/mol. Mono-TFA salt FW: 601.98 g/mol.

4-(2-fluorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (9). TLC (CH_2Cl_2:MeOH 9:1 v/v): [R_f = 0.55; ^{1}H

NMR (300 MHz, CD_3OD, δ): 8.97 (m, 1H), 7.75 (m, 2H), 7.56 (m, 2H), 7.40-7.15 (m, 8H), 6.66 (s, 1H), 3.77 (s, 3H), 3.49 (m, 3H) 3.16 (s, 3H) ESI-MS m/z 488.5 $(M + H^+)^+$ MW: 487.95 g/mol. Mono-TFA salt FW: 601.98 g/mol.

4-(4-Methylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (13). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^1H NMR (300 MHz, CD_3OD, δ): 8.85 (s, 1H), 7.78 (dd, *J* = 9.0, 1.2 Hz, 1H), 7.68 (d, *J* = 9.0 Hz, 1H), 7.56 (d, *J* = 2.1 Hz, 1H), 7.50 (d, *J* = 1.5 Hz, 1H), 7.35 (s, 4H), 7.30 (d, *J* = 7.8 Hz, 2H), 7.23 (d, *J* = 8.1 Hz, 2H), 6.59 (s, 1H), 3.77 (s, 3H), 3.49 (s, 3H), 3.18 (s, 3H) ESI-MS m/z 484.6 $(M + H^+)^+$ MW: 483.99 g/mol. Mono-TFA salt FW: 598.01 g/mol.

4-(3-Methylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (7). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^1H NMR (300 MHz, CD_3OD, δ): 8.96 (s, 1H), 7.77 (dd, *J* = 9.0, 2.1 Hz, 1H), 7.68 (d, *J* = 9.0 Hz, 1H), 7.55 (m, 2H), 7.34 (m, 7H), 7.14 (m, 2H), 6.59 (s, 1H), 3.76 (s, 3H), 3.50 (s, 3H) 3.17 (s, 3H) ESI-MS m/z 484.5 $(M + H^+)^+$ MW: 483.99 g/mol. Mono-TFA salt FW: 598.01 g/mol.

4-(2-Methylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (4). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^1H NMR (300 MHz, CD_3OD, δ): 8.94 (m, 1H), 7.74 (m, 2H), 7.50 (m, 1H), 7.34 (m, 7H), 7.13 (m, 1H), 7.07 (m, 1H), 6.56 (s, 1H), 3.79 (s, 3H), 3.48 (m, 3H) 3.13 (m, 3H), 1.95 (m, 3H) ESI-MS m/z 484.5 $(M + H^+)^+$ MW: 483.99 g/mol. Mono-TFA salt FW: 598.01 g/mol.

4-(2,6-Dimethylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (14). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^1H NMR (300 MHz, CD_3OD, δ): 8.97 (s, 1H), 7.81 (d, *J* = 9.0 Hz, 2.1 Hz, 1H), 7.73 (d, *J* = 9.0 Hz, 1H), 7.50 (d, *J* = 1.5 Hz, 1H), 7.31 (m, 5H), 7.17 (m, 2H), 6.97 (d, *J* = 2.1 Hz, 1H), 6.55 (s, 1H), 3.82 (s, 3H), 3.50 (s, 3H) 3.14 (s, 3H), 1.94 (m, 6H) ESI-MS m/z 498.5 $(M + H^+)^+$ MW: 498.02 g/mol. Mono-TFA salt FW: 612.04 g/mol.

4-(3,5-Dimethylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (17). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.01 (s, 1H), 7.83 (dd, *J* = 9 Hz, 2.1 Hz, 1H), 7.73 (d, *J* = 9 Hz, 1H), 7.60 (m, 2H), 7.39 (m, 4H), 7.17 (s, 1H), 6.99 (m, 2H), 6.62 (s, 1H), 3.81 (s, 3H), 3.56 (s, 3H) 3.23 (s, 3H), 2.39 (s, 6H) [ESI-MS m/z 518.6 $(M + H^+)^+$] MW: 498.02 g/mol. Mono-TFA salt FW: 612.04 g/mol.

4-(3-Trifluoromethylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (8). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.97 (s, 1H), 7.78 (m, 6H), 7.61 (s, 1H), 7.49 (d, *J* = 2.1 Hz, 1H), 7.39 (s, 4H), 6.73 (s, 1H), 3.83 (s, 3H), 3.54 (s, 3H) 3.22 (s, 3H) ESI-MS m/z 538.5 $(M + H^+)^+$ MW: 537.96 g/mol. Mono-TFA salt FW: 651.98 g/mol.

4-(2-Trifluoromethylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (5). This compound was prepared as for analogous compounds but with the following modification. Coupling of 2-trifluoromethylbenzylbromide to the Weinreb amide via was done at 0 ^oC in ether as solvent. TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.97 (m, 1H), 7.80 (m, 5H), 7.48 (m, 1H), 7.34 (m, 5H), 7.35 (m, 5H), 6.96 (m, 1H), 6.65 (s, 1H), 3.83 (s, 3H), 3.50 (m, 3H) 3.14 (m, 3H) ESI-MS m/z 538.4 $(M + H^+)^+$ MW: 537.96 g/mol. Mono-TFA salt FW: 651.98 g/mol.

4-(3-chlorophenyl)-6-((*β*-naphthyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (18). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.62 (s, 1H), 7.82 (m, 4H), 7.71 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.55 (m, 3H), 7.47 (d, *J* = 9.0 Hz, 1H), 7.40 (m, 2H), 7.33 (m, 3H), 7.18 (d, *J* = 7.5 Hz, 1H), 6.72 (s, 1H), 3.77 (s, 3H), 3.52 (s, 3H) 3.24 (s, 3H) ESI-MS m/z 520.5 $(M + H^+)^+$ MW: 520.02 g/mol. Mono-TFA salt FW: 634.04 g/mol.

4-(2,6-Dichlorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (15). TLC (CH_2Cl_2: MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.99 (s, 1H), 7.82 (dd, *J* = 9.0, 1.8 Hz,1H), 7.76 (d, *J* = 9.0 Hz, 1H), 7.55 (m, 4H), 7.35 (m, 4H), 6.95 (d, *J* = 2.1 Hz, 1H), 6.66 (s, 1H), 3.83 (s, 3H), 3.53 (s, 3H) 3.18 (s, 3H), ESI-MS m/z 538.6 $(M + H^+)^+$ MW: 538.85 g/mol. Mono-TFA salt FW: 652.88 g/mol.

4-(3-Chlorophenyl)-6-((4-chlorophenyl)(methylamino)(1-ethyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (25). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.45; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.05 (s, 1H), 7.83 (dd, *J* = 8.7, 1.8 Hz, 1H), 7.77 (d, *J* = 9.0 Hz, 1H), 7.45 (m, 10H), 6.70 (s, 1H), 4.10 (q, 2H), 3.84 (s, 3H), 2.20 (s, 3H), 1.15 (t, 3H) ESI-MS m/z 517.5 $(M + H^+)^+$ MW: 517.45 g/mol. Bis-TFA salt FW: 745.50 g/mol.

4-(3-Chlorophenyl)-6-((4-chlorophenyl)(amino)(1-ethyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (24). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.45; [^{1}H NMR (300 MHz, CD_3OD, δ): 8.98 (s, 1H), 7.85 (m, 2H), 7.46 (m, 4H), 7.32 (m, 1H), 7.22 (m, 4H), 7.02 (s, 1H), 6.85 (d, *J* = 1.5 Hz, 1H), 6.68 (s, 1H), 3.97 (m, 2H), 3.84 (s, 3H), 1.27 (t, 3H) ESI-MS m/z 503.3 $(M + H^+)^+$ MW: 503.42 g/mol. Bis-TFA salt FW: 731.47.

4-(3-Chlorophenyl)-6-((4-chlorophenyl)(methoxy)(1-ethyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (26). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.45; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.15 (s, 1H), 7.85 (dd, *J* = 9.0, 2.1 Hz, 1H), 7.75 (d, *J* = 9.0 Hz, 1H), 7.54 (m, 3H), 7.47 (m, 1H), 7.37 (m, 6H), 6.68 (s, 1H), 4.00 (m, 2H), 3.81 (s, 3H), 3.24 (s, 3H), 1.26 (t, 3H) ESI-MS m/z 518.6 $(M + H^+)^+$ MW: 518.43 g/mol. Mono-TFA salt FW: 632.46 g/mol.

4-(3-Chlorophenyl)-6-((4-chlorophenyl)(hydroxy)(1-ethyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one (27). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.45; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.09 (s, 1H), 7.84 (dd, *J* = 9.0, 2.1 Hz, 1H), 7.78 (d, *J* = 9.0 Hz, 1H) 7.47 (m, 4H), 7.36 (m, 1H), 7.27 (m, 4H), 6.83 (d, *J* = 1.5 Hz, 1H), 6.68 (s, 1H), 4.13 (m,

2H), 3.85 (s, 3H), 1.35 (t, 3H) ESI-MS m/z 504.6 $(M + H^+)^+$ MW: 504.41 g/mol. Mono-TFA salt FW: 618.43 g/mol.

4-(3-Chloro-phenyl)-6-[methoxy-(3-methyl-3*H*-imidazol-4-yl)-p-tolyl-methyl]-1-methyl-1H-quinolin-2-one (28). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.98 (s, 1H), 7.85 (dd, *J* = 9.1 Hz, 2.1 Hz, 1H), 7.73 (d, *J* = 9.0 Hz, 1H), 7.57-7.52 (m, 3H), 7.50 (d, *J* = 3.2 Hz 3H), 7.44-7.43 (m, 1H), 7.36-7.33 (m, 1H), 7.28-7.18 (m, 5H), 6.66 (s, 1H), 3.80 (s, 3H), 3.55 (s, 3H) 3.22 (s, 3H), 2.33 (s, 3H) ESI-MS *m/z* 484.5 $(M + H)^+$ MW: 483.99 g/mol. Mono-TFA salt FW: 598.01 g/mol.

4-(3-Chloro-phenyl)-6-[methoxy-(3-methyl-3*H*-imidazol-4-yl)-(4-trifluromethyl-phenyl)-methyl]-1-methyl-1H-quinolin-2-one (29). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.50; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.01 (s, 1H), 7.88 (dd, *J* = 9.0 Hz, 2.4 Hz, 1H), 7.78- 7.61 (m, 6H), 7.56-7.51 (m, 3H), 7.44-7.43 (m, 1H), 7.38-7.32 (m, 1H), 6.65 (s, 1H), 3.79 (s, 3H), 3.54 (s, 3H) 3.26 (s, 3H) ESI-MS *m/z* 538.5 $(M + H)^+$ MW: 537.96 g/mol. Mono-TFA salt FW: 651.98 g/mol.

4-(3-Chloro-phenyl)-6-[(4-ethyl-phenyl)-methoxy-(3-methyl-3*H*-imidazol-4-yl)-methyl]-1-methyl-1H-quinolin-2-one (30). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.00 (s, 1H), 7.84 (dd, *J* = 9.1 Hz, 3.0 Hz, 1H), 7.74 (d, *J* = 9.0 Hz, 1H), 7.60-7.52 (m, 3H), 7.45-7.43 (m, 1H), 7.37-7.33 (m, 1H), 7.32-7.22 (m, 4H), 6.67 (s, 1H), 3.80 (s, 3H), 3.55 (s, 3H) 3.22 (s, 3H), 2.88 (q, *J* = 3.3 Hz, 1.8 Hz, 2H), 1.21 (t, *J* = 7.2 Hz, 3H) ESI-MS *m/z* 498.5 $(M + H)^+$ MW: 498.02 g/mol. Mono-TFA salt FW: 612.04 g/mol.

4-(3-Chloro-phenyl)-6-[(4-isopropyl-phenyl)-methoxy-(3-methyl-3*H*-imidazol-4-yl)-methyl]-1-methyl-1H-quinolin-2-one (31). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.98 (s, 1H), 7.84 (dd, *J* = 9.3 Hz, 2.4 Hz, 1H), 7.73 (d, *J* = 9.0 Hz, 1H), 7.58-7.51 (m, 4H), 7.46-7.44 (m, 1H), 7.34-7.24 (m, 5H), 6.68 (s, 1H),

3.83(s, 3H), 3.55 (s, 3H) 3.23 (s, 3H), 2.58-2.55 (m, 1H), 1.20 (d, *J* = 6.9 Hz, 6H) ESI-MS *m/z* 512.6 $(M + H)^+$ MW: 511.20 g/mol. Mono-TFA salt FW: 626.07 g/mol.

4-Biphenyl-3-yl-6-[(4-chloro-phenyl)-methoxy-(3-methyl-3*H*-imidazol-4-yl)-methyl]-1-methyl-1H-quinolin-2-one (32). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 8.95 (s, 1H), 7.85-7.70 (m, 3H), 7.69-7.53 (m, 6H), 7.52- 7.48 (m, 2H), 7.45-7.32 (m, 4H), 7.25 (d, *J* = 9.0 Hz, 2H), 6.66 (s, 1H), 4.06 (s, 2H), 3.83 (s, 3H), 3.51 (s, 3H) 3.21 (s, 3H) ESI-MS *m/z* 546.6 $(M + H)^+$ MW: 546.06 g/mol. Mono-TFA salt FW: 660.08 g/mol.

4-(3-Benzyl-phenyl)-6-[(4-chloro-phenyl)-methoxy-(3-methyl-3*H*-imidazol-4-yl)-methyl]-1-methyl-1H-quinolin-2-one (33). TLC (CH_2Cl_2:MeOH 9:1 v/v): R_f = 0.55; ^{1}H NMR (300 MHz, CD_3OD, δ): 9.02 (s, 1H), 7.73 (dd, *J* = 6.6 Hz, 3.0 Hz, 1H), 7.66 (d, *J* = 12.0 Hz, 1H), 7.58 (dd, *J* = 4.5 Hz, 3.0 Hz, 2H), 7.50-7.38 (m, 2H), 7.37-7.20 (m, 11H), 6.61 (s, 1H), 4.06 (s, 2H), 3.78 (s, 3H), 3.51 (s, 3H) 3.24 (s, 3H) ESI-MS *m/z* 560.6 $(M + H)^+$ MW: 560.08 g/mol. Mono-TFA salt FW: 674.11 g/mol.


1/04/06 MeOD m/z = 518, Methyl ether of JK-4
2g
BRUKER
Current Data Parameters
NAME pc010406
EXPNO 1
PROCNO 1
F2 - Acquisition Parameters
Date_ 20070104
Time 9.25
INSTRUM spect
PROBHD 5 mm Multinucl
PULPROG zg
TD 32768
SOLVENT MeOD
NS 8
DS 0
SWH 3396.739 Hz
FIDRES 0.103660 Hz
AQ 4.8234997 sec
RG 181
DW 147.200 usec
DE 6.00 usec
TE 293.4 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec
======== CHANNEL f1 ========
NUC1 1H
P1 12.00 usec
PL1 0.00 dB
SFO1 300.1315352 MHz
F2 - Processing parameters
SI 32768
SF 300.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
ppm
1.00
1.19
1.13
2.21
5.94
1.18
1.01
0.97
0.33
3.20
3.30
4.04
3.13